Studies for Depression and Cognitive and Motor Slowing

Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

The purpose of this research study is to better understand the brain’s dopamine system among adults over the age of 60 years with depression. The dopamine system plays an important role in thinking, movement, motivation, and pleasurable or rewarding activities. In addition to performing brain scans and several different tests of your thinking and movement, we use a medication called carbidopa/levodopa (Sinemet) to investigate how the brain’s dopamine levels influence behavior. Carbidopa/levodopa is approved by the Food and Drug Administration (FDA) for the treatment of Parkinson’s Disease. We are using carbidopa/levodopa “off-label” in this study, which means that it is not approved by the FDA for the treatment of depression. We are interested in studying how carbidopa/levodopa affects the brain’s dopamine levels as well as the mental and physical slowing that occur as people age.

This study is recruiting individuals with/without depression who exhibit physical and/or cognitive slowing. For depressed patients, the study is 8 weeks long; for non-depressed participants, the study can be completed in a few visits. This study involves both MRI and PET scanning.

  • Ages 60+
  • Individuals with/without depression
  • Free treatment with carbidopa/levodopa vs. Placebo for depressed patients
  • Feeling physically and/or mentally slowed down
  • Weekly visits for 8 weeks plus PET and MRI scans
  • Compensation: up to $910.00

LDOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

Similar to the study above, the purpose of this research study is to test whether a medication called carbidopa/levodopa (Sinemet) is helpful for the treatment of depression in older adults. Carbidopa/levodopa is approved by the Food and Drug Administration for the treatment of Parkinson’s Disease. We are using carbidopa/levodopa off-label in this study to see whether it is capable of improving depressive symptoms as well as mental and physical slowing that occur as people age.

This study is recruiting individuals who are depressed and exhibit physical and/or cognitive slowing. The study is 8 weeks long and involves both MRI and PET scanning.

  • Ages 60+
  • Individuals with depression
  • Free treatment with carbidopa/levodopa vs. Placebo
  • Feeling physically and/or mentally slowed down
  • Weekly visits for 8 weeks plus PET and MRI scans
  • Compensation: up to $850.00

Combination Treatment with L-DOPA and Exercise for Mood and Mobility Problems in Later Life

The purpose of this research study is to better understand the brain's dopamine system among older adults with depression. In this research study, you will receive a medication called carbidopa/levodopa (Sinemet). This medication is approved by the Food and Drug Administration for the treatment of Parkinson's Disease. We are using carbidopa/levodopa off-label in this study to see whether it is capable of improving depressive symptoms as well as mental and physical slowing that occur as people age. In addition, you will be required to complete certain exercise routines, in order to determine whether treatment with physical activity affects depression and slowing.

This study is recruiting individuals who are depressed and exhibit physical and/or cognitive slowing. This study is 12 weeks long and involves MRI scanning, as well as at-home exercise routines.

  • Ages 60+
  • Individuals with depression (MDD, current or recurrent)
  • Free treatment with carbidopa/levodopa vs. Placebo
  • Feeling physically and/or mentally slowed down
  • Study visits over 12 weeks, including MRI scans and exercise routine guidance
  • Compensation: up to $350.00

Optimizing Placebo Effects in Older Adults: Enhancing Processing Speed and Executive Functioning with Computerized Cognitive Training

The purpose of this study is to research how cognitive training and antidepressant medications collaboratively improve depressive symptoms in adults ages 60 and older. Participants in this study will complete cognitive training for four weeks, and then subsequently will participate in a medication trial for the next 8 weeks. Participants will complete both neuropsychological testing and MRI scans.

This study is recruiting individuals who are depressed and 60+ years old. The study is 12 weeks long and includes two MRI scans.

  • Ages 60+
  • Individuals with depression (MDD, current or recurrent)
  • Free medication treatment with Escitalopram or Duloxetine (placebo-controlled)
  • Feeling mentally slowed down
  • Study visits over 12 weeks, including MRI scans and cognitive training
  • Compensation: up to $250.00

 

For more information, please call our research staff at (646) 774-8677 or fill out this form.